#Liechtenstein #Vaduz #Implantica #RefluxStop #Acid Reflux

Implantica's Groundbreaking Long-Term Data on RefluxStop®

In an exciting announcement at the Digestive Disease Week (DDW) 2026 in Chicago, Implantica AG revealed groundbreaking long-term outcomes for their innovative RefluxStop® device. This revolutionary treatment aims to address the challenges faced by the estimated one billion people worldwide suffering from acid reflux, a condition that significantly impacts quality of life.

Significant Results from Leading Hospital

Dr. med. Yves Borbély, a prominent surgeon from Inselspital in Bern, Switzerland—the most renowned university hospital in the nation—presented compelling data derived from a comprehensive study of 82 RefluxStop® patients. These individuals were systematically monitored for up to 7.25 years, with remarkable findings indicating that 50% of these patients maintained follow-up for a full four years post-treatment.

The study indicated not only excellent safety but also impressive clinical efficacy. Many patients experienced minimal side effects, and the results affirmed long-held positive expectations associated with the RefluxStop® device. The implications of this study are even more significant given that it encompassed patients with severe complexities, including those suffering from aperistalsis—a condition where the esophagus fails to contract properly—and lung transplant recipients.

Transformative Impact for Complex Cases

The data showcased an encouraging story for patients previously caught in a difficult situation with limited treatment options. Notably, 100% of the participants with aperistalsis were reported to have experienced substantial symptom improvement or complete resolution. This is pivotal because chronic acid reflux can lead to a weakened esophagus, thereby reducing the ability to transport food.

Among the studied patients, 57% demonstrated diminished food transport capability, further underscoring the importance of effective reflux management.

Dr. Borbély expressed, “The RefluxStop long-term outcomes are highly encouraging, even in patient groups where treatment alternatives have historically been inadequate, such as long-term severe sufferers.”

Addressing the Needs of Vulnerable Populations

The study's implications stretch further into the realm of lung transplant patients—approximately 3,000 such surgeries occur annually in the U.S. Acid reflux poses a particular challenge for these individuals, critically affecting lung function and the outcomes of transplantation procedures. Impressively, three lung transplant patients showcased successful treatment with RefluxStop®, with positive results noted even prior to the procedure.

This success introduces a broader perspective on how many more patients with pulmonary diseases might benefit from improved reflux management, especially considering that around 3 million people in the U.S. contend with emphysema and about 14 million face the challenges posed by chronic obstructive pulmonary disease (COPD).

Future Prospects and Economic Impact

Dr. Peter Forsell, the founder and CEO of Implantica, remarked on the momentum that this study brings, emphasizing how it enhances the body of evidence supporting RefluxStop® for severe acid reflux disease. He highlighted that the potential targeted market for RefluxStop could be tenfold greater than existing surgical treatments and eagerly anticipates a broader U.S. launch as they await FDA approval.

Conclusion

Implantica remains dedicated to pioneering advancements in medtech, with RefluxStop® positioning itself as a transformative solution for individuals seeking relief from one of today's most daunting medical challenges. As the findings continue to unfold, both patients and healthcare professionals alike remain hopeful for a future where complex conditions receive the innovative treatments they deserve.